ReviewAsian journal of pharmaceutical sciences2021
SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies.
Review in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.Bioactive materials · 2025Review
- Nature-inspired innovations: unlocking the potential of biomimicry in bionanotechnology and beyond.Discover nano · 2024Review
- Multi-epitopes vaccine design for surface glycoprotein against SARS-CoV-2 using immunoinformatic approach.Heliyon · 2024Article
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
- Ionizable drug delivery systems for efficient and selective gene therapy.Military Medical Research · 2023Review
- Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment.Asian journal of pharmaceutical sciences · 2022Review
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.Molecular biology reports · 2022Review
- Designing multi-epitope based peptide vaccine candidates against SARS-CoV-2 using immunoinformatics approach.BioImpacts : BI · 2022Article
- Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19.Asian journal of pharmaceutical sciences · 2021Article
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.Drug delivery and translational research · 2021Review
- Immunobiology and immunotherapy of COVID-19: A clinically updated overview.Journal of cellular physiology · 2021Review
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- Nanotechnology-based approaches in the fight against SARS-CoV-2.AIMS microbiology · 2021Review
- Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.Journal of the Chinese Medical Association : JCMA · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of a massively producible vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.